SlideShare une entreprise Scribd logo
1  sur  17
Télécharger pour lire hors ligne
Iverson Genetic Diagnostics Warfarin Sensitivity Test
Overview ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Clinical Challenge:  Warfarin Safety •  Widely prescribed  dangerous drug. –  2 million on warfarin, 30 million Rx a year. –  43,000 ER visits a year, 2nd to Insulin for ER adverse drug reaction (ADR) –  87,000 major bleeding events a year. –  17,000 strokes a year. –  10,000 deaths a year. Source: FDA, AEI-Brookings Joint Center, and The Joint Commission
[object Object],[object Object],[object Object],FDA and Joint Commission
Adverse Drug Reactions ,[object Object],[object Object],[object Object],[object Object],[object Object],Source:  AEI-Brookings Joint Center
Risks of Warfarin ADR Strongly Depend on INR Value ,[object Object],[object Object]
Current Methods for Warfarin Dosing ,[object Object],[object Object],[object Object]
Genetics & Warfarin Dosing ,[object Object],[object Object],[object Object],[object Object]
Vitamin K Epoxide Reductase 1 (VKORC1) ,[object Object],[object Object],[object Object],Warfarin  Dose & VKORC1
Cytochrome P450 2C9 (CYP2C9) ,[object Object],[object Object],[object Object],Warfarin  Dose & CYP2C9
Case Study ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Case Study Cont’d ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Without genotype data, this patient would have INR value >4, with potential hemorrhage, and slow return to therapeutic INR
Web-Based Warfarin Dosing Algorithm ,[object Object],[object Object],[object Object],[object Object]
Why Test for Warfarin Sensitivity ? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Personalized Medicine: Each patient on warfarin receives the right dose the first time.
Iverson Operates a CLIA Certified Laboratory ,[object Object],[object Object]
Iverson Provides each Organization with  Tools and Training ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Questions? Iverson Genetic Diagnostics, Inc. 19805 North Creek Parkway, Suite 200 Bothell, Washington 98011 Tel: (425) 318-1332  Fax: (425) 318-1795 Vincent Lecca, Business Deveolpment/Central U.S. 512.627.7723 www. iversongenetics .com

Contenu connexe

Tendances

Integrative regulatory genomics for target gene prioritisation in SLE
Integrative regulatory genomics for target gene prioritisation in SLEIntegrative regulatory genomics for target gene prioritisation in SLE
Integrative regulatory genomics for target gene prioritisation in SLEEnrico Ferrero
 
Galena presentation 9 feb 17
Galena presentation   9 feb 17Galena presentation   9 feb 17
Galena presentation 9 feb 17Galenabio
 
Progress Toward Topical Therapy of AMD
Progress Toward Topical Therapy of AMDProgress Toward Topical Therapy of AMD
Progress Toward Topical Therapy of AMDRick Trevino
 
Emerging targets for migrane
Emerging targets for migraneEmerging targets for migrane
Emerging targets for migraneGULAM NAVI AZAD
 
Fatal combination !
Fatal combination !Fatal combination !
Fatal combination !Ali Alwan
 
2014 crpc,cspc how to treat
2014 crpc,cspc how to treat2014 crpc,cspc how to treat
2014 crpc,cspc how to treatGuan-lin Huang
 
Using WES in Distant Relationships to Identify Cardiomyopathy Genes
Using WES in Distant Relationships to Identify Cardiomyopathy GenesUsing WES in Distant Relationships to Identify Cardiomyopathy Genes
Using WES in Distant Relationships to Identify Cardiomyopathy GenesGolden Helix Inc
 
Galena presentation 28 nov 16
Galena presentation   28 nov 16Galena presentation   28 nov 16
Galena presentation 28 nov 16Galenabio
 
Evolving concepts in her2 evaluation in breast cancer
Evolving concepts in her2 evaluation in breast cancerEvolving concepts in her2 evaluation in breast cancer
Evolving concepts in her2 evaluation in breast cancerDattatreya Mukherjee
 
Comparison of Glucose and Hemoglobin Concentration in Transplant Patients Tre...
Comparison of Glucose and Hemoglobin Concentration in Transplant Patients Tre...Comparison of Glucose and Hemoglobin Concentration in Transplant Patients Tre...
Comparison of Glucose and Hemoglobin Concentration in Transplant Patients Tre...Pediatric Nephrology
 
An Exploration of Clinical Workflows in VarSeq
An Exploration of Clinical Workflows in VarSeqAn Exploration of Clinical Workflows in VarSeq
An Exploration of Clinical Workflows in VarSeqGolden Helix
 
BioSig Technologies Corporate Summary - May 2015
BioSig Technologies Corporate Summary - May 2015BioSig Technologies Corporate Summary - May 2015
BioSig Technologies Corporate Summary - May 2015Greg Cash
 
Gene Therapy Challenges and Success
Gene Therapy Challenges and SuccessGene Therapy Challenges and Success
Gene Therapy Challenges and Successijtsrd
 
Vicissitudes of target validation for BACE1 and BACE2
Vicissitudes of target validation for BACE1 and BACE2 Vicissitudes of target validation for BACE1 and BACE2
Vicissitudes of target validation for BACE1 and BACE2 Chris Southan
 

Tendances (19)

Integrative regulatory genomics for target gene prioritisation in SLE
Integrative regulatory genomics for target gene prioritisation in SLEIntegrative regulatory genomics for target gene prioritisation in SLE
Integrative regulatory genomics for target gene prioritisation in SLE
 
Galena presentation 9 feb 17
Galena presentation   9 feb 17Galena presentation   9 feb 17
Galena presentation 9 feb 17
 
Progress Toward Topical Therapy of AMD
Progress Toward Topical Therapy of AMDProgress Toward Topical Therapy of AMD
Progress Toward Topical Therapy of AMD
 
Hypertension devices - neurostimulation
Hypertension devices - neurostimulationHypertension devices - neurostimulation
Hypertension devices - neurostimulation
 
Emerging targets for migrane
Emerging targets for migraneEmerging targets for migrane
Emerging targets for migrane
 
ASHP poster
ASHP posterASHP poster
ASHP poster
 
Fatal combination !
Fatal combination !Fatal combination !
Fatal combination !
 
2014 crpc,cspc how to treat
2014 crpc,cspc how to treat2014 crpc,cspc how to treat
2014 crpc,cspc how to treat
 
Using WES in Distant Relationships to Identify Cardiomyopathy Genes
Using WES in Distant Relationships to Identify Cardiomyopathy GenesUsing WES in Distant Relationships to Identify Cardiomyopathy Genes
Using WES in Distant Relationships to Identify Cardiomyopathy Genes
 
Galena presentation 28 nov 16
Galena presentation   28 nov 16Galena presentation   28 nov 16
Galena presentation 28 nov 16
 
Hemostasis in txa
Hemostasis in txaHemostasis in txa
Hemostasis in txa
 
Evolving concepts in her2 evaluation in breast cancer
Evolving concepts in her2 evaluation in breast cancerEvolving concepts in her2 evaluation in breast cancer
Evolving concepts in her2 evaluation in breast cancer
 
Comparison of Glucose and Hemoglobin Concentration in Transplant Patients Tre...
Comparison of Glucose and Hemoglobin Concentration in Transplant Patients Tre...Comparison of Glucose and Hemoglobin Concentration in Transplant Patients Tre...
Comparison of Glucose and Hemoglobin Concentration in Transplant Patients Tre...
 
calcineurin Inhibitors
calcineurin Inhibitorscalcineurin Inhibitors
calcineurin Inhibitors
 
An Exploration of Clinical Workflows in VarSeq
An Exploration of Clinical Workflows in VarSeqAn Exploration of Clinical Workflows in VarSeq
An Exploration of Clinical Workflows in VarSeq
 
Challenges in cni inhibitor
Challenges in cni inhibitor  Challenges in cni inhibitor
Challenges in cni inhibitor
 
BioSig Technologies Corporate Summary - May 2015
BioSig Technologies Corporate Summary - May 2015BioSig Technologies Corporate Summary - May 2015
BioSig Technologies Corporate Summary - May 2015
 
Gene Therapy Challenges and Success
Gene Therapy Challenges and SuccessGene Therapy Challenges and Success
Gene Therapy Challenges and Success
 
Vicissitudes of target validation for BACE1 and BACE2
Vicissitudes of target validation for BACE1 and BACE2 Vicissitudes of target validation for BACE1 and BACE2
Vicissitudes of target validation for BACE1 and BACE2
 

Similaire à Iverson Genetic Testing Client Presentation

Warfarin presentation Hani alghamdi
Warfarin presentation Hani alghamdiWarfarin presentation Hani alghamdi
Warfarin presentation Hani alghamdiHaniAlghamdi16
 
Oral anticoagulants ppt
Oral anticoagulants ppt Oral anticoagulants ppt
Oral anticoagulants ppt Shalini Garg
 
Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...
Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...
Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...Innovation Agency
 
Cadth 2015 e5 noac ad symposium_panel_14apr2015
Cadth 2015 e5 noac ad symposium_panel_14apr2015Cadth 2015 e5 noac ad symposium_panel_14apr2015
Cadth 2015 e5 noac ad symposium_panel_14apr2015CADTH Symposium
 
Rivaroxaban versus Warfarina en el tratamiento de la Fibrilación Auricular
Rivaroxaban versus Warfarina en el tratamiento de la Fibrilación AuricularRivaroxaban versus Warfarina en el tratamiento de la Fibrilación Auricular
Rivaroxaban versus Warfarina en el tratamiento de la Fibrilación AuricularHospital Guadix
 
voyager pad.pptx
voyager pad.pptxvoyager pad.pptx
voyager pad.pptxakifab93
 
Surgion sweming in blood pool Central Hospital
Surgion sweming in blood pool   Central HospitalSurgion sweming in blood pool   Central Hospital
Surgion sweming in blood pool Central HospitalHusni Ajaj
 
Pharmacy news 2014
Pharmacy news 2014Pharmacy news 2014
Pharmacy news 2014munaoqal
 
molecular markers for antimalarial drug resistance
molecular markers for antimalarial drug resistancemolecular markers for antimalarial drug resistance
molecular markers for antimalarial drug resistanceAnil kumar
 
Darbepoetin scientific information and comparison
Darbepoetin scientific information and comparisonDarbepoetin scientific information and comparison
Darbepoetin scientific information and comparisonHarsh shaH
 
Anticoagulants d
Anticoagulants dAnticoagulants d
Anticoagulants dSara Saber
 
Oral Surgery in Patients on Anticoagulant Therapy
Oral Surgery in Patients on Anticoagulant TherapyOral Surgery in Patients on Anticoagulant Therapy
Oral Surgery in Patients on Anticoagulant TherapyVarun Mittal
 

Similaire à Iverson Genetic Testing Client Presentation (20)

Warfarin presentation Hani alghamdi
Warfarin presentation Hani alghamdiWarfarin presentation Hani alghamdi
Warfarin presentation Hani alghamdi
 
Oral anticoagulants ppt
Oral anticoagulants ppt Oral anticoagulants ppt
Oral anticoagulants ppt
 
NOAC poster
NOAC posterNOAC poster
NOAC poster
 
Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...
Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...
Dr Andrea Jorgensen - The future of innovation in atrial fibrillation and str...
 
Cadth 2015 e5 noac ad symposium_panel_14apr2015
Cadth 2015 e5 noac ad symposium_panel_14apr2015Cadth 2015 e5 noac ad symposium_panel_14apr2015
Cadth 2015 e5 noac ad symposium_panel_14apr2015
 
Enoxaparin
EnoxaparinEnoxaparin
Enoxaparin
 
Rivaroxaban versus Warfarina en el tratamiento de la Fibrilación Auricular
Rivaroxaban versus Warfarina en el tratamiento de la Fibrilación AuricularRivaroxaban versus Warfarina en el tratamiento de la Fibrilación Auricular
Rivaroxaban versus Warfarina en el tratamiento de la Fibrilación Auricular
 
B042207013
B042207013B042207013
B042207013
 
voyager pad.pptx
voyager pad.pptxvoyager pad.pptx
voyager pad.pptx
 
Surgion sweming in blood pool Central Hospital
Surgion sweming in blood pool   Central HospitalSurgion sweming in blood pool   Central Hospital
Surgion sweming in blood pool Central Hospital
 
Oral anticoagulant
Oral anticoagulant Oral anticoagulant
Oral anticoagulant
 
Pharmacy news 2014
Pharmacy news 2014Pharmacy news 2014
Pharmacy news 2014
 
Observacional de ivermectina
Observacional de ivermectinaObservacional de ivermectina
Observacional de ivermectina
 
Warfarin Versus Rivaroxaban in Provoked DVT
Warfarin Versus Rivaroxaban in Provoked DVTWarfarin Versus Rivaroxaban in Provoked DVT
Warfarin Versus Rivaroxaban in Provoked DVT
 
molecular markers for antimalarial drug resistance
molecular markers for antimalarial drug resistancemolecular markers for antimalarial drug resistance
molecular markers for antimalarial drug resistance
 
Darbepoetin scientific information and comparison
Darbepoetin scientific information and comparisonDarbepoetin scientific information and comparison
Darbepoetin scientific information and comparison
 
Anticoagulants d
Anticoagulants dAnticoagulants d
Anticoagulants d
 
Treatment with anticoagulation
Treatment with anticoagulationTreatment with anticoagulation
Treatment with anticoagulation
 
Oral Surgery in Patients on Anticoagulant Therapy
Oral Surgery in Patients on Anticoagulant TherapyOral Surgery in Patients on Anticoagulant Therapy
Oral Surgery in Patients on Anticoagulant Therapy
 
Treatment options for Corona Virus.pptx
Treatment options for Corona Virus.pptxTreatment options for Corona Virus.pptx
Treatment options for Corona Virus.pptx
 

Iverson Genetic Testing Client Presentation

  • 1. Iverson Genetic Diagnostics Warfarin Sensitivity Test
  • 2.
  • 3. Clinical Challenge: Warfarin Safety • Widely prescribed dangerous drug. – 2 million on warfarin, 30 million Rx a year. – 43,000 ER visits a year, 2nd to Insulin for ER adverse drug reaction (ADR) – 87,000 major bleeding events a year. – 17,000 strokes a year. – 10,000 deaths a year. Source: FDA, AEI-Brookings Joint Center, and The Joint Commission
  • 4.
  • 5.
  • 6.
  • 7.
  • 8.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17. Questions? Iverson Genetic Diagnostics, Inc. 19805 North Creek Parkway, Suite 200 Bothell, Washington 98011 Tel: (425) 318-1332 Fax: (425) 318-1795 Vincent Lecca, Business Deveolpment/Central U.S. 512.627.7723 www. iversongenetics .com